View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
June 1, 2020

Abiomed receives EUA for Impella RP in Covid-19 patients

By Chloe Kent

Abiomed has received Emergency Use Authorisation (EUA) from the US Food and Drug Administration (FDA) for the use of its Impella RP temporary heart pump in patients suffering from right side heart failure or decompensation related to Covid-19.

The Impella RP received FDA approval in 2017 for treating right ventricular failure in the setting of acute myocardial infarction and after cardiac surgery. Biventricular cardiac support can be provided when Impella RP is used in combination with left-side Impella devices.

Covid-19 can cause acute pulmonary embolism, which may lead to acute right ventricular failure. The FDA has concluded that the Impella RP may be effective at providing temporary support in these cases.

Topics in this article: , , ,
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU